Skip to main content

This Request for Proposal submission closed on January 19, 2021. This competition will provide up to 15 awards of up to $40,000 each (direct costs) along two tracks, with a specific emphasis on projects capable of significant impact within 1-2 years:

Track 1 projects are standard 1-year basic or translational pilot project proposals, with an endpoint of a competitive peer-reviewed extramural grant application.

  • Projects to acquire key preliminary data for a planned submission/resubmission of a peer-reviewed extramural grant, especially to NCI.
  • Special consideration is to applications supporting resubmissions that generate new data in response to prior critiques.

Track 2 projects are Early Phase Clinical Research project proposals, with an endpoint of an interventional investigator-initiated treatment trial at UC Irvine Health within a 2-year time frame.

  • Trials must be managed by the Stern Center for Cancer Clinical Trials & Research.
  • Projects must be initiated from a Disease-Oriented Team or a multidisciplinary tumor board, must include a DOT-approved clinical protocol and should have full regulatory approval within 6 months of award. While Track 2 projects are not necessarily expected to lead to extramural peer-reviewed funding, pharmaceutical industry co-sponsorship is encouraged.


The following FOCUS AREAS will be especially competitive:

  • Research addressing health disparities1 in the Cancer Center’s Catchment Area of Orange County. This includes:
    • Cancers with unusually high incidence or prevalence in the catchment area, such as melanoma, breast and lung cancer
    • Cancers disproportionately affecting racial or ethnic groups, such as liver and gastric cancer in Hispanics and Asians, cervical, gall bladder, and young onset colorectal cancer in Hispanics
  • Projects addressing unique aspects of a specific cancer burden in the catchment area (e.g., etiology of lung adenocarcinoma in Asian female never-smokers or of Ph-like B-lymphoblastic leukemia in Hispanics; basis for low HPV vaccination rates in different racial/ethnic groups; melanoma detection/prognosis in Hispanics)
  • Projects addressing research questions in population health and cancer control (etiology and/or prevention) relevant to the catchment area, particularly involving collaborations between Cancer Control Program members & other CFCCC Programs
  • Projects addressing cancers of relevance to pediatric/AYA populations
  • Collaborations involving Disease-Oriented Teams or multidisciplinary tumor boards that seek to advance a novel diagnostic or screening technology, therapeutic molecule or device, or bio-behavioral intervention to a clinical trial
  • Projects leveraging CFCCC Shared Resources
  • Applications from Early Stage Investigators

1 The NCI defines cancer health disparities as “adverse differences in cancer incidence (new cases), cancer prevalence (existing cases), cancer death (mortality), cancer survivorship, and burden of cancer related conditions that exist among specific population groups in the United States.”